<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Lori</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Healey, Jeffrey S.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The RE-LY AF Registry</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-23</style></pages><abstract><style  face="normal" font="default" size="100%">Around the world, the average 1-year mortality rate is 10% for patients with a diagnosis of atrial fibrillation (AF) who present to an emergency department for any reason. AF is a major global disease, most of what is known about the disorder is based on studies conducted in Europe and North America. The baseline results from the Randomized Evaluation of Long-Term Anticoagulation Therapy [RE-LY AF] registry demonstrated important regional variations in risk factors and treatment of AF across 47 countries.</style></abstract><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>